FGFR2 and cholangiocarcinoma: A report showed that cells expressing FGFR2-CLIP1 fusion were sensitive to INCB054828 (a pan-FGFR inhibitor) in cholangiocarcinoma while the FGFR2 N549H mutation was resistant to this inhibitor (Krook et al., 2019).